globalgenes.org
Changing a Treatment Landscape by De-Risking Drug Development
Andrew Rosen, CEO of the National Ataxia Foundation, discusses the challenges of developing therapies for spinocerebellar ataxia, the critical role of patient-led organizations in early-stage research...